Clinical Trial Update: Ticilimumab (CP-675,206) in Treating Patients With Stage IIIC or Stage IV Melanoma [Phase 2]

View source ↗

Summary

Phase 2 trial update for ticilimumab (CP-675,206) in stage IIIC or stage IV melanoma; results posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• CP-675,206
• Ticilimumab (ticilimumab)

Snippet

Sponsor: Jonsson Comprehensive Cancer Center | Conditions: Melanoma (Skin) | Phase 2 | Status: COMPLETED | Results posted: 2020-10-26